Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE
Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE
复制标题
DOI：
10.1177/0961203316640922
复制
发表时间：
2016-07-01
期刊：
影响因子：
2.6
通讯作者：
Hiepe, F.
中科院分区：
文献类型：
--
作者：
Biesen, R.;Rose, T.;Hiepe, F.
系统性红斑狼疮（SLE）是一种神秘的疾病，表现出极其不同的临床表型。生物标志物已经成为疾病活动性的诊断、评估和监测、临床表现的鉴别诊断、病程预测和分层治疗的非常有用的工具，是SLE个体化治疗的关键。我们总结了只能由自身抗体、补体成分和干扰素生物标志物提供的临床信息。
Systemic lupus erythematosus (SLE) can be a mysterious disease, presenting with extremely divergent clinical phenotypes. Already, biomarkers are very helpful tools for diagnosis, assessment and monitoring of disease activity, differential diagnosis of clinical manifestations, prediction of the disease course and stratified therapy, and they hold the key to personalized medicine in SLE. We summarize the clinical information that can only be supplied by autoantibodies, complement components and interferon biomarkers in this diverse disease.